Validation of HPLC and UV spectrophotometric methods for the determination of bezafibrate in pharmaceutical formulations

Journal of Liquid Chromatography and Related Technologies

Volumn 31, Issue 2, 2008, Pages 269-280

  De Melo, Janine ^a   Hurtado, Felipe Kellermann ^a   Prado, Anelise Weich ^a   Souza, Marinês Jost E ^a   Rolim, Clarice Madalena Bueno ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Bezafibrate; Liquid chromatography; Pharmaceutical formulations; Spectrophotometry; Validation

Indexed keywords

ACETONITRILE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METHANOL; PH EFFECTS; ULTRAVIOLET SPECTROPHOTOMETERS;

BEZAFIBRATE; PHARMACEUTICAL FORMULATIONS;

DRUG PRODUCTS;

ACETONITRILE; BEZAFIBRATE; METHANOL; PHOSPHATE BUFFERED SALINE;

ACCURACY; ANALYTIC METHOD; ARTICLE; DRUG DETERMINATION; DRUG FORMULATION; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PH; ULTRAVIOLET SPECTROPHOTOMETRY; VALIDATION PROCESS;

EID: 37249019122     PISSN: 10826076     EISSN: 1520572X     Source Type: Journal    
DOI: 10.1080/10826070701739108     Document Type: Article

References (14)

1. Pater, C. The current status of primary prevention of heart disease. Curr. Control. Trials Cardiovasc. Med. 2001, 2, 24-37.
2. Hirano, T.; Kazumi, T.; Yoshino, G. Long-term efficacy of bezafibrate in reduction of small, dense low-density lipoprotein by hypotriglyceridemic action. Curr. Ther. Res. 2000, 61, 127-136.
3. 30th United States Pharmacopeia; United States Pharmacopeial Convention: Rockville, MD, 2006.
4. Komsta, L.; Misztal, G.; Majchrzak, E.; Hauzer, A. Separation of fibrate-type antihyperlipidemic drugs by capillary electrophoresis and their quantitation in pharmaceuticals. J. Pharm. Biomed. Anal. 2006, 41, 408-414.
5. Krebs, A.; Starczewska, B.; Leszczynska, E. Spectrophotometric determination of bezafibrate by ternary complex formation with palladium (II) chloride and eosin. Anal. Lett. 2006, 39, 2453-2462.
6. Komsta, L.; Misztal, G. Application of UV-derivative spectra for determination of four antihyperlipidaemic drugs in pharmaceutical formulations. Acta Pol. Pharm. 2004, 61, 9-13.
7. Misztal, G.; Komsta, L. Study of the liquid chromatography retention of some fibrate-type antihyperlipidemic drugs on C18 and CN columns: application for quantitation in pharmaceutical formulations. J. AOAC Int. 2005, 88, 479-489.
8. Masnatta, L.D.; Cuniberti, L.A.; Rey, R.H.; Werba, J.P. Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high performance liquid chromatography. J. Chromatogr. B 1996, 687, 437-442.
9. Castoldi, D.; Monzani, V.; Tofanetti, O. Determination of bezafibrate in human plasma and urine by high performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 1985, 344, 259-265.
10. Ledermann, H.; Kaufman, B. Comparative pharmacokinetics of 400 mg bezafibrate after a single oral administration of a new slow-release preparation and the currently available commercial form. J. Int. Med. Res. 1981, 9, 516-520.
11. Gandini, R.; Assereto, R.; Castoldi, D.; Cunietti, E.; Garanzelli, P.; Monzani, W. Normal and slow-release formulations of bezafibrate: a comparative pharmacokinetic study in man. Pak. J. Pharm. Sci. 1987, 7, 149-155.
12. Vens-Cappell, B.; Hilgenstock, C.; Gellert, M.; Kuhle, K.; Reifferscheid, I.; Winckler, P.; Buhrens, K.G. Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 1. Single-dose administration. 2. Multiple-dose administration and chronopharmacokinetics. Arzneimittelforschung 1993, 43, 346-356.
13. Ali, O.; Khan, M.A.; Obaid, R.; Ahmed, S.W. Bioavailability study of tablet bezafibrate 200 mg (Lipocor). Pak. J. Pharm. Sci. 2002, 15, 35-4.
14. ICH - international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Validation of Analytical Procedures: Text and Methodology; ICH Secretariat: Geneva, Switzerland, 1996.